Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with or without Corticosteroids in Primary Membranous Nephropathy
NCT05514015Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab in primary membranous nephropathy (PMN) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Complete Response Rate at 12 months. Started Mar 2024; status: recruiting.
02
Drugs
rituximab
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05514015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514015.